Key statistics
As of last trade Ionis Pharmaceuticals Inc (ISI:MUN) traded at 68.74, -4.82% below its 52-week high of 72.22, set on Feb 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 68.74 |
|---|---|
| High | 68.74 |
| Low | 68.74 |
| Bid | 68.16 |
| Offer | 69.34 |
| Previous close | 68.74 |
| Average volume | 83.71 |
|---|---|
| Shares outstanding | 165.19m |
| Free float | 160.71m |
| P/E (TTM) | -- |
| Market cap | 13.41bn USD |
| EPS (TTM) | -2.47 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 07:04 GMT.
More ▼
- Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
- Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
- Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
- Ionis to present at upcoming investor conferences
- Ionis updates time for fourth quarter and full year 2025 financial results webcast
- Ionis to hold fourth quarter and full year 2025 financial results webcast
- DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
- Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
- Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
- Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
More ▼
